New research suggests an experimental osteoporosis drug called denosumab may help reduce fracture risk in patients with nonmetastatic prostate cancer.
A study published in The New England Journal of Medicine concluded Denosumab was associated with increased bone mineral density and reduced the incidence of new vertebral fractures in men receiving androgen-deprivation therapy for nonmetastatic prostate cancer.
The Food and Drug Administration advisory committee recommended the drug for women being treated for osteoporosis and men experiencing bone loss from prostate cancer treatments, reports the LA Times. While the recommendation means the drug's makers, Amgen Inc., are one step closer to have denosumab approved, the FDA won't officially decide until October.
Researchers randomly assigned prostate cancer patients to receive either a subcutaneous 60 mg dose of denosumab or a placebo every six months for 36 months. Changes in bone mineral densities at the femoral neck and total hip were measured, along with any new vertebral fractures at 24 months and 36 months.
Overall findings suggest bone mineral density of the lumbar spin increased by 5.6% in the denosumab group as compared with a loss of 1%t in the placebo group. Significant differences between the groups were seen as early as 1 month and sustained throughout the 26 month period.
What are your thoughts about this drug? Share your thoughts about denosumab or your current cancer treatment experiences at our Prostate Cancer Message Board.